Randomized, controlled, double-blind trial to investigate the effect of colchicin on the endothelial function in patients with CHIP mutations and chronic heart failure with reduced left ventricular function (CHIP-HF)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518383-12-00

Acronym

COL-CHIPHF-P24

Enrollment

100

Registered

2024-11-05

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic heart failure

Brief summary

Difference in FMD measurements in HFrEF patients with and without CHIP mutations before and after Colchicin or Placebo treatment

Interventions

DRUGFüllstoff DAC in hard gelatine capsules is used as placebo. Füllstoff DAC consists of mannitol 99.5% and colloidal Silicon Dioxide 0.5%

DRUGColchicin Ysat 0

DRUG5 mg Tabletten

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Difference in FMD measurements in HFrEF patients with and without CHIP mutations before and after Colchicin or Placebo treatment	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026